Drs Sandhya Srinivas and Aria F. Olumi discuss barriers to prostate cancer screening, diagnosis and treatment for transgender patients, and ways to provide gender-affirming, wraparound care. Relevant disclosures can be found with the episode sh

Which Metastatic Hormone-Sensitive Prostate Cancer Patients Are the Best Candidates for Doublet and Triplet Therapies?

Oct 24th, 2023 22m 20s

Drs Sandhya Srinivas and Tanya B. Dorff discuss metastatic hormone-sensitive prostate cancer, which patients are the best candidates for doublets vs triplets, and how we pick these patients. Relevant disclosures can be found with the episode sh

New Therapies for Metastatic Castrate-Resistant Prostate Cancer: Radioligand Therapy and PSMA Biomarker-Based Imaging

Sep 21st, 2023 21m 36s

Drs Sandhya Srinivas and Oliver Sartor discuss the VISION study, new therapies for patients with metastatic castrate-resistant prostate cancer, and PSMA biomarker-based imaging. Relevant disclosures can be found with the episode show notes on M

Germline vs Somatic Testing for Patients With Prostate Cancer: Which Patients Should Be Evaluated and When?

Aug 23rd, 2023 22m 42s

Drs Sandhya Srinivas and Heather Cheng discuss PARP inhibitors, clinical trials, and germline vs somatic testing for patients with prostate cancer, as well as the optimal time for this testing. Relevant disclosures can be found with the episode

Effective Treatment Options and Sequencing for Patients With Castration-Resistant Prostate Cancer

Jul 19th, 2023 23m 24s

Drs Sandhya Srinivas and Shilpa Gupta discuss castration-resistant prostate cancer and the sequence, method of therapy, and specific patient populations in which these drugs will be most effective. Relevant disclosures can be found with the epi

Androgen Deprivation Therapy and Prostate Cancer: Bone Health, Survivorship, and Side Effects

Jul 19th, 2023 21m 51s

Drs Sandhya Srinivas and Rana R. McKay discuss bone health and survivorship, including risk factors and potential side effects with androgen deprivation therapy in patients with prostate cancer. Relevant disclosures can be found with the episod

Rate